PMID- 15772576
OWN - NLM
STAT- MEDLINE
DCOM- 20050419
LR  - 20191109
IS  - 0761-8417 (Print)
IS  - 0761-8417 (Linking)
VI  - 61
IP  - 1 Pt 1
DP  - 2005 Feb
TI  - [Treatment of anemia and bone metastasis in metastatic non-small-cell lung 
      cancer. A French survey].
PG  - 23-9
AB  - Use of erythropoietin (EPO) for chemotherapy-induced anemia and biphosphonates 
      (BP) for bone metastasis has increased steadily. However, there are no guidelines 
      on their use in many situations such as non small cell lung carcinoma (NSCLC), 
      which frequently alters quality of life markedly. Therefore, a multicentric 
      survey was designed to assess the treatment of anemia and bone metastasis in 
      chemotherapy-treated patients with non-small-cell lung carcinoma. Nine 
      representative centers of the oncology working party of the French respiratory 
      society (Groupe d'Oncologie de la Societe de Pneumologie de Langue Francaise) 
      participated. Inclusion criteria were stage IV NSCLC and at least one course of 
      chemotherapy in the last 3 months. A total of 148 and 50 patients (pts) were 
      included in the anemia and bone metastasis surveys, respectively. Anemia was 
      present in 60.8% of patients, and was not treated in 75%; 15 patients received 
      EPO (10.1%). Independent predictors of EPO use were presence of anemia-related 
      symptoms, hemoglobin level, age and center: the rate of prescription in patients 
      with anemia varied from 13 to 73% between centers. BP were administered in 38% of 
      patients with bone metastasis. Independent predictors of BP use were calcium 
      serum level, pain, and center with a rate of prescription ranging from 0 to 80% 
      between centers. This study reveals that, in France, most patients with anemia 
      are not treated, EPO being seldom prescribed. The use of both EPO and BP is 
      highly variable between centers. Guidelines on the use of these supportive 
      treatments could help improve the care for lung cancer patients receiving 
      chemotherapy.
FAU - Brechot, J-M
AU  - Brechot JM
AD  - Service d'Oncologie Medicale, Hopital Avicenne, AP-HP, 125, route de Stalingrad, 
      93009 Bobigny Cedex. jeanne-marie.brechot@avc.ap-hop-paris.fr
FAU - Roche, N
AU  - Roche N
FAU - Marichy, C
AU  - Marichy C
FAU - Lebeau, B
AU  - Lebeau B
FAU - Debieuvre, D
AU  - Debieuvre D
FAU - Darneau, G
AU  - Darneau G
FAU - Coste, E
AU  - Coste E
FAU - Grivaux, M
AU  - Grivaux M
FAU - Falchero, L
AU  - Falchero L
FAU - Vlastos, F
AU  - Vlastos F
FAU - Souquet, P-J
AU  - Souquet PJ
CN  - Groupe d'Oncologie de la Societe de Pneumologie de Langue Francaise
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
TT  - Prise en charge de l'anemie et des metastases osseuses dans les cancers 
      bronchiques non a petites cellules (CBNPC) metastases. Une enquete francaise.
PL  - France
TA  - Rev Pneumol Clin
JT  - Revue de pneumologie clinique
JID - 8406312
RN  - 0 (Diphosphonates)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Anemia/*chemically induced/drug therapy
MH  - Bone Neoplasms/drug therapy/*secondary
MH  - Carcinoma, Non-Small-Cell Lung/*complications/drug therapy/*secondary
MH  - Diphosphonates/therapeutic use
MH  - Erythropoietin/therapeutic use
MH  - France
MH  - Health Surveys
MH  - Humans
MH  - Lung Neoplasms/*complications/drug therapy/*pathology
MH  - *Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'/statistics & numerical data
MH  - Quality of Life
EDAT- 2005/03/18 09:00
MHDA- 2005/04/20 09:00
CRDT- 2005/03/18 09:00
PHST- 2005/03/18 09:00 [pubmed]
PHST- 2005/04/20 09:00 [medline]
PHST- 2005/03/18 09:00 [entrez]
AID - MDOI-RPC-03-2005-61-1-0761-8417-101019-200513076 [pii]
AID - 10.1016/s0761-8417(05)84778-9 [doi]
PST - ppublish
SO  - Rev Pneumol Clin. 2005 Feb;61(1 Pt 1):23-9. doi: 10.1016/s0761-8417(05)84778-9.